CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

AI Briefing

• – CRISPR Therapeutics AG issues $550 million convertible senior notes due 2031, upsized from $350 million, expected to close on March 16, 2026.
• – The offering is priced through a private offering to qualified institutional buyers under Rule 144A under the Securities Act.
• – CRISPR Therapeutics AG granted initial purchasers the option to purchase up to an additional $50 million aggregate principal amount of notes.